BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong KCW, Hui EP, Lo KW, Lam WKJ, Johnson D, Li L, Tao Q, Chan KCA, To KF, King AD, Ma BBY, Chan ATC. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol 2021. [PMID: 34194007 DOI: 10.1038/s41571-021-00524-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Shen H, Yin J, Niu R, Lian Y, Huang Y, Tu C, Liu D, Wang X, Lan X, Yuan X, Zhang J. Development and validation of a radiomic nomogram to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study. Radiotherapy and Oncology 2022. [DOI: 10.1016/j.radonc.2022.04.017] [Reference Citation Analysis]
2 Ai QH, Hung KF, So TY, Mo FKF, Tsung Anthony Chin W, Hui EP, Ma BBY, Ying M, King AD. Prognostic value of cervical nodal necrosis on staging imaging of nasopharyngeal carcinoma in era of intensity-modulated radiotherapy: a systematic review and meta-analysis. Cancer Imaging 2022;22:24. [PMID: 35596198 DOI: 10.1186/s40644-022-00462-6] [Reference Citation Analysis]
3 Münz C. Modification of EBV-Associated Pathologies and Immune Control by Coinfections. Front Oncol 2021;11:756480. [PMID: 34778072 DOI: 10.3389/fonc.2021.756480] [Reference Citation Analysis]
4 Diez-Fraile A, De Ceulaer J, Derpoorter C, Spaas C, De Backer T, Lamoral P, Abeloos J, Lammens T. Tracking the Molecular Fingerprint of Head and Neck Cancer for Recurrence Detection in Liquid Biopsies. Int J Mol Sci 2022;23:2403. [PMID: 35269544 DOI: 10.3390/ijms23052403] [Reference Citation Analysis]
5 Li W, Liu Q, Wang H, Zhang H, Liu Q, Hu L, Li H, Dai J, Sun X, Yu H, Wang D. Innovative application of internal carotid artery embolization in salvage endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma: A case-matched comparison. Int Forum Allergy Rhinol 2021. [PMID: 34773719 DOI: 10.1002/alr.22927] [Reference Citation Analysis]
6 Liu Y, Wen J, Huang W. Exosomes in nasopharyngeal carcinoma. Clin Chim Acta 2021;523:355-64. [PMID: 34666030 DOI: 10.1016/j.cca.2021.10.013] [Reference Citation Analysis]
7 Faraji F, Ramirez SI, Anguiano Quiroz PY, Mendez-Molina AN, Gutkind JS. Genomic Hippo Pathway Alterations and Persistent YAP/TAZ Activation: New Hallmarks in Head and Neck Cancer. Cells 2022;11:1370. [PMID: 35456049 DOI: 10.3390/cells11081370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Qiu X, Wu H, Xu T, Xie S, You Z, Hu Y, Zheng Y, Liang Z, Huang C, Yi L, Li L, Liu J, Fei Z, Chen C. Reflecting on the utility of standardized uptake values on 18F-FDG PET in nasopharyngeal carcinoma. BMC Cancer 2022;22:495. [PMID: 35513804 DOI: 10.1186/s12885-022-09626-w] [Reference Citation Analysis]
9 Gao P, Peng W, Hu Y. Prognostic and clinicopathological significance of lymphocyte-to-monocyte ratio in patients with nasopharyngeal carcinoma: A meta-analysis. Head Neck 2022. [PMID: 35050540 DOI: 10.1002/hed.26952] [Reference Citation Analysis]
10 Liu GY, Li WZ, Wang DS, Liang H, Lv X, Ye YF, Zhao C, Ke LR, Lv SH, Lu N, Bei WX, Cai ZC, Chen X, Liang CX, Guo X, Xia WX, Xiang YQ. Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2022. [PMID: 35175316 DOI: 10.1001/jamaoncol.2021.7366] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
11 Li WZ, Lv X, Hu D, Lv SH, Liu GY, Liang H, Ye YF, Yang W, Zhang HX, Yuan TZ, Wang DS, Lu N, Ke LR, Tang WB, Tong LH, Chen ZJ, Liu T, Cao KJ, Mo HY, Guo L, Zhao C, Chen MY, Chen QY, Huang PY, Sun R, Qiu F, Luo DH, Wang L, Hua YJ, Tang LQ, Qian CN, Mai HQ, Guo X, Xiang YQ, Xia WX. Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol 2022. [PMID: 35323856 DOI: 10.1001/jamaoncol.2022.0122] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Xu J, Wei X, Wang Y, Wang F. Current status and advances of immunotherapy in nasopharyngeal carcinoma. Ther Adv Med Oncol 2022;14:175883592210962. [DOI: 10.1177/17588359221096214] [Reference Citation Analysis]
13 Cw. Wong K, Johnson D, Hui EP, Ct. Lam R, By. Ma B, Tc. Chan A. Opportunities and Challenges in Combining Immunotherapy and Radiotherapy in Head and Neck Cancers. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Twu CW, Lin PJ, Tsou HH, Liu YC, Jiang RS, Liang KL, Lin TY, Wang WY, Lin JC. Maintenance metronomic chemotherapy for metastatic/recurrent nasopharyngeal carcinoma. Head Neck 2022;44:1453-61. [PMID: 35362634 DOI: 10.1002/hed.27044] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Li Y, Liao Z, Wang R, Liang Z, Lin Z, Deng S, Chen L, Liu Z, Feng S. Long non-coding RNA SPRY4-IT1 promotes proliferation and metastasis in nasopharyngeal carcinoma cell. PeerJ 2022;10:e13221. [DOI: 10.7717/peerj.13221] [Reference Citation Analysis]
16 Wei Y, Wang Y, Li H, Wang C, Liu S, Huang Z, Wang G, Tao Y, Xia Y. A Nomogram to Predict Survival in Patients With Locoregional Recurrent Nasopharyngeal Carcinoma Receiving Comprehensive Treatment. Front Oncol 2022;12:892510. [DOI: 10.3389/fonc.2022.892510] [Reference Citation Analysis]
17 Wu CF, Lin L, Mao YP, Deng B, Lv JW, Zheng WH, Wen DW, Kou J, Chen FP, Yang XL, Xu SS, Ma J, Zhou GQ, Sun Y. Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA. BMC Med 2021;19:193. [PMID: 34433440 DOI: 10.1186/s12916-021-02076-4] [Reference Citation Analysis]
18 Mi J, Ma S, Chen W, Kang M, Xu M, Liu C, Li B, Wu F, Liu F, Zhang Y, Wang R, Jiang L. Integrative Pan-Cancer Analysis of KIF15 Reveals Its Diagnosis and Prognosis Value in Nasopharyngeal Carcinoma. Front Oncol 2022;12:772816. [DOI: 10.3389/fonc.2022.772816] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chan D, Lam W, Hui E, Ma B, Chan C, Lee V, Cheng S, Gai W, Jiang P, Wong K, Mo F, Zee B, King A, Le Q, Chan A, Chan K, Lo Y. Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasma. Annals of Oncology 2022. [DOI: 10.1016/j.annonc.2022.04.068] [Reference Citation Analysis]